Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

Breast Cancer Research and Treatment

Volumn 135, Issue 2, 2012, Pages 505-517

  Daemen, Anneleen ^a,b   Wolf, Denise M ^a   Korkola, James E ^b   Griffith, Obi L ^b   Frankum, Jessica R ^c   Brough, Rachel ^c   Jakkula, Lakshmi R ^b   Wang, Nicholas J ^b   Natrajan, Rachael ^c   Reis Filho, Jorge S ^c   Lord, Christopher J ^c   Ashworth, Alan ^c   Spellman, Paul T ^b   Gray, Joe W ^d   Van'T Veer, Laura J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d Oregon Health and Science University Department of Biomedical Engineering   (United States)

Author keywords

Bioinformatics; Biomarker; Breast cancer; Olaparib; PARP

Indexed keywords

BRCA1 PROTEIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MRE11 PROTEIN; MRE11A PROTEIN; NIBRIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; OLAPARIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; XRCC3 PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA REPAIR; DRUG RESPONSE; DRUG SENSITIVITY; HOMOLOGOUS RECOMBINATION; MEIOTIC PROPHASE I; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA REPAIR; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASMS, BASAL CELL; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; STATISTICS, NONPARAMETRIC; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84866559001     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2188-0     Document Type: Article

References (56)

1. Rich T, Allen RL, Wyllie AH (2000) Defying death after DNA damage. Nature 407(6805):777-783. doi:10.1038/35037717
2. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39-85. doi:10.1146/ annurev.biochem.73.011303.073723 (Pubitemid 39050363)
3. Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40(2):179-204. doi:10.1016/j. molcel.2010.09.019
4. Iglehart JD, Silver DP (2009) Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 361(2):189-191. doi:10.1056/NEJMe0903044
5. Ashworth A, Lord CJ, Reis-Filho JS (2011) Genetic interactions in cancer progression and treatment. Cell 145(1):30-38. doi: 10.1016/j.cell.2011.03.020
6. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 434(7035):913-917. doi:10.1038/ nature03443 (Pubitemid 40559005)
7. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917-921. doi:10.1038/nature03445 (Pubitemid 40559006)
8. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1(6-7):315-322. doi:10.1002/emmm.2009 00041
9. Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, Ashworth A, Reis-Filho JS (2010) PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2(53):53ra75. doi:10.1126/ scitranslmed.3001538
10. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Eccles D, Evans DG, Renwick A, Seal S, Lord CJ, Ashworth A, Reis-Filho JS, Antoniou AC, Rahman N (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43(9):879-882. doi:10.1038/ng.893
11. Buisson R, Dion-Cote AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, Stasiak A, Xia B, Masson JY (2010) Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 17(10):1247-1254. doi:10.1038/nsmb.1915
12. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10(4):293-301. doi:10.1038/nrc2812
13. Caldecott KW (2007) Mammalian single-strand break repair: mechanisms and links with chromatin. DNA Repair 6(4):443-453. doi:10.1016/j.dnarep.2006.10.006 (Pubitemid 46357048)
14. Liang H, Tan A (2011) PARP inhibitors. Curr Breast Cancer Rep 3:44-54
15. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66(16):8109-8115. doi: 10.1158/0008-5472.CAN-06-0140 (Pubitemid 44299177)
16. Williamson CT, Muzik H, Turhan AG, Zamo A, O'Connor MJ, Bebb DG, Lees-Miller SP (2010) ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 9(2):347-357. doi:10.1158/1535-7163.MCT-09-0872
17. Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4(10):814-819. doi: 10.1038/nrc1457 (Pubitemid 39331153)
18. Vinayak S, Ford J (2010) PARP inhibitors for the treatment and prevention of breast cancer. Curr Breast Cancer Rep 2:190-197
19. Plummer R (2011) Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? Breast Cancer Res 13(4):218. doi:10.1186/bcr2877
20. Turner NC, Ashworth A (2011) Biomarkers of PARP inhibitor sensitivity. Breast Cancer Res Treat 127(1):283-286. doi:10.1007/ s10549-011-1375-8
21. Guha M (2011) PARP inhibitors stumble in breast cancer. Nat Biotechnol 29(5):373-374. doi:10.1038/nbt0511-373
22. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(-ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235-244. doi:10.1016/S0140-6736 (10)60892-6
23. Dent R, Lindeman G, Clemons M, Wildiers H, Chan A, McCarthy N, Singer C, Lowe E, Kemsley K, Carmichael J (2010) Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the 1st or 2nd line treatment of patients with metastatic triple negative breast cancer: results from the safety cohort of a Phase 1/2 multicentre trial. Proc Am Soc Clin Oncol 28(suppl):abstr 1018
24. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12(9):852-861. doi:10.1016/S1470-2045(11)70214-5
25. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-134. doi:10.1056/NEJMoa 0900212
26. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182):1111-1115. doi:10.1038/nature06548 (Pubitemid 351317441)
27. Weigelt B, Warne PH, Downward J (2011) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30(29):3222-3233. doi:10.1038/onc.2011.42
28. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT (2012) Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 109(8):2724-2729. doi: 10.1073/pnas.1018854108
29. Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, Pusztai L (2010) Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 9(5):1120-1127. doi: 10.1158/1535-7163.MCT-09-1117
30. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW(2006)Acollection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515-527. doi:10.1016/j.ccr.2006.10.008 (Pubitemid 44854747)
31. Wang X, Weaver D (2011) The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res 1(3):301-327
32. Holstege H, Horlings HM, Velds A, Langerod A, Borresen-Dale AL, van de Vijver MJ, Nederlof PM, Jonkers J (2010) BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 10:654. doi:10.1186/1471-2407-10-654
33. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM (2006) Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5(10):2512-2521. doi:10.1158/1535-7163.MCT-06-0334 (Pubitemid 44650915)
34. Goncalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, Borg JP, Chaffanet M, Viens P, Birnbaum D, Bertucci F (2011) Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat 127(1):273-281. doi:10.1007/s10549-010-1199-y
35. Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W (2011) Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 458(1):55-64. doi:10.1007/ s00428-010-0988-3
36. Cotter M, Pierce A, McGowan P, Madden S, Flanagan L, Quinn C, Evoy D, Crown J, McDermott E, Duffy M (2011) PARP1 in triple-negative breast cancer: expression and therapeutic potential. J Clin Oncol 29 (15-suppl):1061
37. Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, Curtin NJ (2009) Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer 101(2):256-262. doi:10.1038/sj.bjc.6605166
38. Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jumppanen M, Staaf J, Jonsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R, Borg A (2008) Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40(1):102-107. doi:10.1038/ng.2007.39
39. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235. doi:10.1007/s10549-006-9242-8 (Pubitemid 44631925)
40. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC (2010) A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 16(24):6159-6168. doi: 10.1158/1078-0432.CCR-10-1027
41. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M (2010) KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 38(Database issue):D355-360. doi:10.1093/nar/gkp896
42. Gudmundsdottir K, Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25(43):5864-5874. doi:10.1038/sj.onc. 1209874 (Pubitemid 44453442)
43. Tutt A, Ashworth A (2002) The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8(12):571-576 (Pubitemid 35408215)
44. CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74(6):1175-1182. doi: 10.1086/421251 (Pubitemid 38669316)
45. Fletcher O, Johnson N, Dos Santos Silva I, Kilpivaara O, Aittomaki K, Blomqvist C, Nevanlinna H, Wasielewski M, Meijers-Heijerboer H, Broeks A, Schmidt MK, Van't Veer LJ, Bremer M, Dork T, Chekmariova EV, Sokolenko AP, Imyanitov EN, HamannU, Rashid MU, Brauch H, Justenhoven C, Ashworth A, Peto J (2009) Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev 18(1):230-234. doi:10.1158/1055-9965.EPI-08- 0416
46. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM-and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11(2):175-189. doi:10.1016/j.ccr.2006. 11.024 (Pubitemid 46209849)
47. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MA, Wang X, Linding R, Ong SE, Weaver D, Carr SA, Yaffe MB (2010) DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell 40(1):34-49. doi: 10.1016/j.molcel. 2010.09.018
48. Williams GJ, Lees-Miller SP, Tainer JA (2010) Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. DNA Repair 9(12):1299-1306. doi:10.1016/j.dnarep.2010. 10.001
49. The Cancer Genome Atlas Data Portal. http://tcga-data.nci.nih. gov/tcga/tcgaHome2.jsp. Accessed 13 Jan 2012
50. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, Demichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, Van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N (2011) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/ 150012; ACRIN 6657). Breast Cancer Res Treat. doi: 10.1007/s10549-011-1895-2. Accessed 13 Jan 2012
51. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. J Am Med Assoc 305(18):1873-1881. doi:10.1001/jama.2011.593
52. Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, IniestaMD,Morgan MA,Rennert G, GruberSB (2011) MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition inmicrosatellite unstable colorectal cancers. Cancer Res 71(7):2632-2642. doi:10.1158/0008-5472.CAN-10- 1120
53. Wen Q, Scorah J, Phear G, Rodgers G, Rodgers S, Meuth M (2008) A mutant allele of MRE11 found in mismatch repairdeficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. Mol Biol Cell 19(4):1693-1705. doi:10.1091/mbc.E07-09-0975 (Pubitemid 351805121)
54. Koberle B, Masters JR, Hartley JA, Wood RD (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9(5):273-276 (Pubitemid 29139312)
55. Okano S, Kanno S, Nakajima S, Yasui A (2000) Cellular responses and repair of single-strand breaks introduced by UV damage endonuclease in mammalian cells. J Biol Chem 275(42):32635-32641. doi:10.1074/jbc.M004085200
56. Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC (2010) DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 123(1):189-196. doi:10.1007/s10549-010-0983-z